Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2021-09-22 Report Publication Anno…
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
ERYTECH annonce la mise à disposition de son rapport financier semestriel 2021
Report Publication Announcement Classification · 1% confidence The document title is "ERYTECH annonce la mise à disposition de son rapport financier semestriel 2021" (ERYTECH announces the availability of its 2021 semi-annual financial report). The text explicitly states that the company has filed its 'rapport financier semestriel' (semi-annual financial report) with the AMF for the six months ended June 30, 2021. This content is an announcement about the publication of a periodic financial report, not the comprehensive report itself (which would likely be classified as IR or ER if it were the full results). Since the document's primary purpose is to announce that a report has been published and is available for consultation, it fits the definition of a Report Publication Announcement (RPA). The document length (3777 chars) is also short, supporting the RPA classification over the full report classification (IR).
2021-09-22 French
ERYTECH Announces the Availability of its Half-Year Financial Report 2021
Report Publication Announcement Classification · 1% confidence The document is titled "ERYTECH Announces the Availability of its Half-Year Financial Report 2021". It explicitly states that the company "announced that it had filed with the Autorité des Marchés Financiers (AMF) its half-year report for the six-month period ended June 30, 2021." The document itself is short (3449 characters) and serves primarily to announce that the actual report is available elsewhere (on the corporate website). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points to a Report Publication Announcement (RPA). The content is not the comprehensive Interim/Quarterly Report (IR) itself, but the notice of its publication.
2021-09-22 English
Rapport financier semestriel 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL' (Semi-Annual Financial Report) for the period ending June 30, 2021. It includes a formal declaration by the CEO, a detailed management report on activities, and comprehensive financial tables (income statement components, R&D expenses, and administrative expenses) comparing the first half of 2020 and 2021. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2021
2021-09-21 French
ERYTECH fait le point sur ses activités et publie ses résultats semestriels 2021
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2021 (S1 2021) for ERYTECH Pharma. It includes detailed financial statements (income statement, cash position), management's discussion and analysis of business trends, clinical trial updates, and future outlook. It is not merely an announcement of a report, but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). H2 2021
2021-09-20 French
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2021, containing detailed financial tables (income statement, cash position), management's discussion of business highlights, clinical trial updates, and future outlook. It is not merely an announcement of a report, but the report itself, containing substantive financial data. Therefore, it fits the definition of an Interim/Quarterly Report (IR). H2 2021
2021-09-20 English
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that ERYTECH Pharma will host a conference call and webcast on September 21, 2021, to discuss its Second Quarter 2021 operational highlights. The text explicitly details the date, time, registration links, and access codes for a conference call, which is the defining characteristic of an announcement related to an earnings or business update call. This fits the definition of a Call Transcript (CT) if it were the transcript itself, but since this is the *announcement* of the call, it is most closely related to the event that generates a CT. However, looking at the provided definitions, 'Call Transcript (Code: CT)' is for the full text transcript. This document is an announcement *about* the call, not the transcript itself. It is not a full Earnings Release (ER) which usually contains the summarized results. Given the focus on scheduling and accessing the call, and the short length (3575 chars), it functions as a notification. Since there is no specific category for 'Conference Call Announcement', the closest related category that deals with scheduled events involving financial updates is often grouped with Earnings Releases (ER) or sometimes treated as a general Regulatory Filing (RNS). However, the content is purely about scheduling a call to discuss operational highlights, which is a precursor to an earnings release or a standalone business update call. In many classification schemes, announcements of earnings calls are classified as ER or CT precursors. Given the options, and the fact that it is an announcement about a call where results/updates will be discussed, it is most likely intended to be classified as an Earnings Release (ER) announcement, or if strictly interpreted, a Regulatory Filing (RNS) if it doesn't contain the actual results. Since it is announcing a call to discuss Q2 2021 operational highlights, it serves the function of an ER announcement. If the document contained the actual Q2 results, it would be ER. Since it only announces the call, it is a precursor. I will classify it as ER based on the subject matter (Quarterly call announcement), as it is the most relevant financial event category, even though it's not the release itself. If the document were longer and contained the results, it would definitively be ER. Given the ambiguity, ER is the best fit for a quarterly update announcement.
2021-09-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.